The high specificity that occurred in all drug types indicates that Health Canada and the FDA are usually in broad agreement on which drugs shouldnothave priority review status.
The high specificity that occurred in all drug types indicates thatHealth Canada and the FDA are usually in broad agreement onwhich drugs shouldnothave priority review status.